The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Dyskinesia LEAPS, 2012Xenon Inhalation to Reduce L-DOPA-Induced Dyskinesia
Levodopa is the most effective drug to treat symptoms of Parkinson’s disease, however long-term use leads to disabling L-DOPA-induced dyskinesia (LID) in the vast majority of patients. NMDA receptor...
-
MJFF Research Grant, 2012Intrinsic Remodeling of the Fovea in Parkinson’s Disease
Promising Outcomes of Original Grant:
In the past we determined the part of the retina (the back of the eye) which needs to be measured for PD induced changes. We developed an equation which permits... -
MJFF Research Grant, 2012Bay Area Solvent Study - Symptoms (BASS-S)
Objective/Rationale:
Chlorinated solvents are commonly used in a variety of occupations. The solvents trichloroethylene (TCE) and perchloroethylene (PERC) have been associated with an... -
Rapid Response Innovation Awards, 2013Alpha-synuclein Picobody: A Novel Blood-Brain Barrier Permeable Diagnostic Ligand for Parkinson's Disease
Objective/Rationale:
The presence of the blood-brain barrier (BBB) has been an insurmountable impediment to successful drug delivery to the central nervous system. To circumvent the BBB... -
Research Grant, 2013Utility of a Novel Nicotinic Receptor Agonist for Treating Levodopa-induced Dyskinesia
Objective/Rationale:
It has been suggested that a nicotinic acetylcholine receptor (nAChR) agonists may restore the deficits caused by the loss of nicotinic acetylcholine subunits found in Parkinson’s... -
Research Grant, 2012Phase I-B Clinical Trial of AVE8112 for Cognitive Impairment in Parkinson’s Disease
Objective/Rationale:
Cognitive impairment is a symptom seen in Parkinson’s disease (PD) patients, and some can progress to dementia. AVE8112 is a PDE4 inhibitor that was in development by the...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.